European Commission approves Briviact (brivaracetam) an adjunctive therapy in the treatment of partial-onset seizures- UCB

UCB announced the European Commission (EC) has approved Briviact (brivaracetam) as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization (spreading to both sides of the brain after the initial seizure) in adult and adolescent patients from 16 years of age with epilepsy. Briviact treatment is initiated without titration, meaning patients receive a therapeutic dose of the drug from the first day of treatment. First launches in EU countries are set to begin Q1 2016.

Comment: In trials, brivaracetam significantly reduced the frequency of seizures compared to placebo, with a 50% reduction in seizures seen in up to 40% of patients treated with UCB's drug.